Search results
Is Pfizer's Pain Sarepta Therapeutics' Gain? Don't Bet on It. | The Motley Fool
The Motley Fool· 7 hours agoIn mid-June, Pfizer's (PFE -0.71%) gene-therapy candidate to treat Duchenne muscular dystrophy (DMD)...
Sarepta's Stock Soars on Best-Case FDA Decision for its Muscular Dystrophy Treatment
The Wall Street Journal· 5 days agoFor biotech companies, regulatory approval is usually one of many steps needed to convince Wall...
Insider Sale: EVP, General Counsel Ryan Brown Sells 38,957 Shares of Sarepta Therapeutics Inc (SRPT)
GuruFocus.com via Yahoo Finance· 13 hours agoThe price-earnings ratio of the company stands at 395.15, significantly above both the industry...
Sarepta jumps on broad approval for muscular dystrophy drug - The Boston Globe
The Boston Globe· 6 days agoSarepta shares surged 36% in extended trading at 5:51 p.m. in New York. The drug’s approval was...
FDA Expands Sarepta's (SRPT) DMD Gene Therapy Label
Zacks via Yahoo Finance· 5 days agoFollowing the label expansion, Sarepta's (SRPT) Elevidys is approved to treat all DMD patients aged four years and older, regardless of ambulation...
Sarepta Catapults 30% After Hitting A 'Grand Slam' Approval In Muscular Dystrophy
Investor's Business Daily· 5 days agoSarepta stock rocketed Friday after hitting a "grand slam" approval that expands the market for its...
Sarepta Therapeutics (NASDAQ:SRPT) Price Target Increased to $200.00 by Analysts at BMO Capital...
ETF DAILY NEWS· 2 days agoBMO Capital Markets currently has an outperform rating on the biotechnology company’s stock. Cantor...
Sarepta Stock Surges On FDA News; Industrial Stock In Buy Zone
Investor's Business Daily· 5 days agoShares are in the 5% buy zone up 221.13, to according to MarketSurge pattern recognition. Honeywell'...
Sarepta’s Elevidys secures US label expansion for DMD
Pharmaceutical Technology via Yahoo Finance· 5 days agoBased on its functional benefits, Elevidys was granted traditional approval for ambulatory patients...
Duchenne approval exposes FDA rift over Sarepta gene therapy
BioPharma Dive via Yahoo Finance· 5 days agoPeter Marks’ decision to override the objections of agency staff and broaden use of Elevidys could...